Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma
Aclaris reported positive Phase 1b proof-of-concept results for its anti-TSLP/IL-4Rα bispecific ATI-052 in atopic dermatitis and asthma, with both trials meeting their primary objectives. In severe AD, ATI-052 delivered a 45% placebo-adjusted EASI improvement and 43% placebo-adjusted itch improvement at day 57; a single dose cut FeNO 59% and improved FEV1 by 200 ml in asthma at day 15. Safety was clean, with no Grade 3/4 adverse events and no conjunctivitis observed. Aclaris will prioritize Phase 2b development in eosinophilic esophagitis, with a trial expected to start early next year.
Key figures
- Drug Name
- ATI-052
- Phase Of Trial
- Phase 1b
- Patients ad trial
- 14
- Feno reduction day15
- 59%
- Patients asthma trial
- 16
- Fev1 improvement day15
- 200 ml
- Proteome normalization week8
- 95%
- Easi placebo adjusted improvement
- 45%
- Itch placebo adjusted improvement day57
- 43%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.